Home Business Breaking shareholder Asia Pharmaceuticals’ net profit fell for 2 years after listing, investment bank Dongxing Securities earned 60 million

Breaking shareholder Asia Pharmaceuticals’ net profit fell for 2 years after listing, investment bank Dongxing Securities earned 60 million

by admin
Breaking shareholder Asia Pharmaceuticals’ net profit fell for 2 years after listing, investment bank Dongxing Securities earned 60 million

Original title: After the listing of the shareholder Yapharm, the net profit fell for 2 years, and the investment bank Dongxing Securities earned 60 million

China Economic Net, Beijing, April 1. Today, the stock price of East Asia Pharmaceutical (605177.SH) fell. As of the closing price, it was 24.48 yuan, down 4.78%, with a turnover of 68.3783 million yuan, an amplitude of 2.80%, a turnover rate of 4.92%, and a total market value. 2.781 billion yuan.

East Asia Pharmaceutical was listed on the main board of the Shanghai Stock Exchange on November 25, 2020, with an issue price of 31.13 yuan per share. On February 8, 2021, East Asia Pharmaceuticals fell below the issue price intraday.

Yesterday evening, East Asia Pharmaceutical disclosed its 2021 annual report. In 2021, East Asia Pharmaceuticals achieved operating income of 712 million yuan, a year-on-year decrease of 19.22%; realized a net profit attributable to shareholders of listed companies of 68.4921 million yuan, a year-on-year decrease of 40.17%; realized a net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses. The profit was 47.6963 million yuan, a year-on-year decrease of 53.88%; the net cash flow from operating activities was -23.5994 million yuan, a year-on-year decrease of 116.06%.

East Asia Pharmaceutical was listed on the main board of the Shanghai Stock Exchange, with 28.40 million shares issued (all of which were new shares issued by the company), the sponsor was Dongxing Securities Co., Ltd., and the sponsor representatives were Ruan Yingbo and Zhang Yu.

The total amount of funds raised by East Asia Pharmaceuticals is 884 million yuan. After deducting the issuance expenses, the net amount of funds raised is 782 million yuan, which will be used for the “technical transformation project of annual production of 7-ACCA 200 tons and 7-ANCA 60 tons of key intermediates of cephalosporins”. , “Phase II of Cephalosporin API Industry Upgrading Project with an Annual Output of 586 Tons”, “R&D Center Construction Project”, “Supplementary Working Capital Project”.

See also  The latest list of industries with a slight net outflow of northbound funds this week (list) _ Oriental Fortune Net

East Asia Pharmaceuticals issued a total of 102 million yuan, of which the sponsor Dongxing Securities Co., Ltd. received 61.4387 million yuan of sponsorship and underwriting fees.

In 2020, the year East Asia Pharmaceuticals went public, the company’s operating income and net profit have already declined.

In 2020, East Asia Pharmaceuticals achieved operating income of 882 million yuan, a year-on-year decrease of 10.77%; realized a net profit of 114 million yuan attributable to shareholders of listed companies, a year-on-year decrease of 31.99%; realized a net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses The profit was 103 million yuan, a year-on-year decrease of 32.76%; the net cash flow from operating activities was 147 million yuan, a year-on-year decrease of 32.19%.

Return to Sohu, see more


Editor:

Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy